Strategic Global Advisors LLC Buys New Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Strategic Global Advisors acquired 4,823 Alnylam Pharmaceuticals shares in the second quarter, valued at approximately $1.45 million. Institutional investors collectively own 92.97% of the company, with several major funds also establishing new positions.
• Alnylam reported quarterly EPS of $1.84, beating estimates of $1.63, while revenue rose 66.9% year over year to $1.29 billion, slightly below analyst expectations.
• Analyst sentiment remains positive but mixed, with a consensus “Moderate Buy” rating and an average price target of $386.14, despite several firms recently lowering their targets.

Strategic Global Advisors LLC bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 4,823 shares of the biopharmaceutical company's stock, valued at approximately $1,452,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Caisse de depot et placement du Quebec purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $25,813,000. Man Group plc acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $51,448,000. Jupiter Topco LLC acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $40,808,000. Canada Pension Plan Investment Board purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $100,618,000. Finally, Parkman Healthcare Partners LLC purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $15,254,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director David E. I. Pyott sold 3,830 shares of the business's stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. The trade was a 70.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company's stock.

Alnylam Pharmaceuticals Trading Down 0.4%

NASDAQ:ALNY opened at $239.00 on Thursday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $197.81 and a 1 year high of $495.55. The stock has a market cap of $31.98 billion, a P/E ratio of 44.42 and a beta of 0.30. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The stock has a 50-day simple moving average of $264.27 and a 200-day simple moving average of $294.77.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The business's quarterly revenue was up 66.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.51) EPS. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on ALNY. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, July 31st. Oppenheimer cut their price objective on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an "outperform" rating on the stock in a research report on Friday, July 31st. Raymond James Financial upgraded Alnylam Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a $420.00 price objective on the stock in a research note on Monday, August 3rd. Royal Bank Of Canada decreased their target price on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an "outperform" rating for the company in a report on Friday, July 31st. Finally, Wall Street Zen cut Alnylam Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $386.14.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source